24.79
price up icon0.41%   0.10
after-market アフターアワーズ: 24.78 -0.010 -0.04%
loading
前日終値:
$24.69
開ける:
$25.25
24時間の取引高:
705.77K
Relative Volume:
0.98
時価総額:
$975.44M
収益:
$734.86M
当期純損益:
$5.14M
株価収益率:
198.32
EPS:
0.125
ネットキャッシュフロー:
$132.71M
1週間 パフォーマンス:
-2.44%
1か月 パフォーマンス:
+9.21%
6か月 パフォーマンス:
+13.46%
1年 パフォーマンス:
-3.95%
1日の値動き範囲:
Value
$24.74
$25.60
1週間の範囲:
Value
$23.47
$27.13
52週間の値動き範囲:
Value
$18.80
$27.64

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name
名前
Pacira Biosciences Inc
Name
セクター
Healthcare (1106)
Name
電話
650-242-8052
Name
住所
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Name
職員
829
Name
Twitter
Name
次回の収益日
2026-04-30
Name
最新のSEC提出書
Name
PCRX's Discussions on Twitter

Compare PCRX vs TAK, ZTS, TEVA, HLN, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
PCRX icon
PCRX
Pacira Biosciences Inc
24.79 971.50M 734.86M 5.14M 132.71M 0.125
TAK icon
TAK
Takeda Pharmaceutical Co Adr
16.55 52.32B 29.85B 776.90M 4.35B 0.2408
ZTS icon
ZTS
Zoetis Inc
112.54 47.38B 9.47B 2.67B 2.28B 6.0218
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
35.86 41.16B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
9.17 41.02B 14.54B 2.22B 2.58B 0.4871
UTHR icon
UTHR
United Therapeutics Corp
572.20 24.67B 3.18B 1.33B 1.04B 27.90

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-09 開始されました Barclays Equal Weight
2025-11-17 開始されました H.C. Wainwright Buy
2025-07-25 アップグレード Truist Hold → Buy
2025-01-30 アップグレード Truist Sell → Hold
2024-08-13 ダウングレード Truist Buy → Sell
2024-08-12 ダウングレード JP Morgan Overweight → Underweight
2024-08-12 ダウングレード Piper Sandler Overweight → Neutral
2024-08-12 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-08-12 ダウングレード Raymond James Outperform → Mkt Perform
2024-07-03 ダウングレード Barclays Overweight → Equal Weight
2024-03-07 再開されました JP Morgan Overweight
2023-12-20 開始されました Raymond James Outperform
2023-08-03 アップグレード TD Cowen Market Perform → Outperform
2023-01-31 再開されました Wedbush Outperform
2022-10-21 再開されました Jefferies Buy
2022-01-03 再開されました JP Morgan Overweight
2021-07-26 アップグレード JP Morgan Neutral → Overweight
2021-04-21 再開されました JP Morgan Neutral
2021-04-09 開始されました Berenberg Buy
2021-04-07 再開されました RBC Capital Mkts Outperform
2021-02-11 ダウングレード Northland Capital Outperform → Market Perform
2021-01-21 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-09-21 アップグレード Northland Capital Market Perform → Outperform
2020-07-06 繰り返されました Needham Buy
2020-05-27 開始されました Guggenheim Neutral
2020-04-07 開始されました Northland Capital Outperform
2020-03-20 アップグレード SVB Leerink Mkt Perform → Outperform
2020-02-24 繰り返されました H.C. Wainwright Buy
2020-01-24 開始されました SunTrust Buy
2020-01-23 開始されました SunTrust Buy
2019-11-06 開始されました BTIG Research Buy
2019-06-11 開始されました Barclays Overweight
2019-05-06 アップグレード Mizuho Underperform → Neutral
2019-05-02 アップグレード Stifel Sell → Hold
2019-02-01 ダウングレード Mizuho Neutral → Underperform
2018-08-06 ダウングレード BofA/Merrill Buy → Neutral
2018-04-09 繰り返されました H.C. Wainwright Buy
2018-03-21 繰り返されました Mizuho Neutral
2018-02-16 ダウングレード Needham Buy → Hold
2018-01-19 開始されました Seaport Global Securities Buy
2018-01-04 繰り返されました Canaccord Genuity Buy
2018-01-03 開始されました Leerink Partners Mkt Perform
すべてを表示

Pacira Biosciences Inc (PCRX) 最新ニュース

pulisher
May 05, 2026

Pacira BioSciences Mails Letter to Stockholders - The Manila Times

May 05, 2026
pulisher
May 05, 2026

PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety - ChartMill

May 05, 2026
pulisher
May 04, 2026

How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors - Sahm

May 04, 2026
pulisher
May 03, 2026

Price-Driven Insight from (PCRX) for Rule-Based Strategy - Stock Traders Daily

May 03, 2026
pulisher
May 03, 2026

Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data - Yahoo Finance

May 03, 2026
pulisher
May 02, 2026

Pacira Biosciences Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Sales Forecast Maintained - Moomoo

May 02, 2026
pulisher
May 02, 2026

Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat

May 02, 2026
pulisher
May 02, 2026

Pacira BioSciences (PCRX) Return To Profitability Tests Bullish Growth Narratives - Sahm

May 02, 2026
pulisher
May 02, 2026

Pacira BioSciences Reports Strong First Quarter Growth for EXPAREL - HarianBasis.co

May 02, 2026
pulisher
May 01, 2026

MSN Money - MSN

May 01, 2026
pulisher
May 01, 2026

PCRX Maintained by RBC Capital -- Price Target Raised to $24 - GuruFocus

May 01, 2026
pulisher
May 01, 2026

PCRX Maintained by Needham -- Price Target Raised to $32 - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - The Globe and Mail

May 01, 2026
pulisher
May 01, 2026

Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price - MarketBeat

May 01, 2026
pulisher
May 01, 2026

Pacira BioSciences Stock (US6951271005): Analyst Rating Change and Price Move on May 1, 2026 - AD HOC NEWS

May 01, 2026
pulisher
May 01, 2026

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst Upgrade - MarketBeat

May 01, 2026
pulisher
May 01, 2026

RBC Raises Price Target on Pacira Biosciences to $24 From $22, Keeps Sector Perform Rating - marketscreener.com

May 01, 2026
pulisher
May 01, 2026

Vanguard Capital Management (PCRX) reports 2.09M-share stake in Pacira - Stock Titan

May 01, 2026
pulisher
May 01, 2026

Vanguard Portfolio Management (PCRX) reports 2.59M shares, 6.38% stake - Stock Titan

May 01, 2026
pulisher
May 01, 2026

Pacira (PCRX) Q1 2026 Earnings Call Transcript - AOL.com

May 01, 2026
pulisher
May 01, 2026

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - Yahoo Finance

May 01, 2026
pulisher
May 01, 2026

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2026 Earnings Call Transcript - Insider Monkey

May 01, 2026
pulisher
May 01, 2026

Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - The Motley Fool

May 01, 2026
pulisher
May 01, 2026

Pacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst Challenges - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Pacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestones - MSN

May 01, 2026
pulisher
Apr 30, 2026

Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences Q1 2026 Earnings Call Transcript - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences Q1 Earnings Call Highlights - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-04-30 - Seeking Alpha

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences : Corporate Sustainability Report (pacira corporate sustainability report 2024 v1 20260430) - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Is Pacira BioSciences (PCRX) Undervalued After Q1 2026? GAAP EPS - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

PCRX Sets Ambitious Goals for FY26 with Strong Clinical Focus - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Do options traders know something about Pacira BioSciences stock we don't? - MSN

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences (PCRX) Reports Strong Q1 Revenue Growth - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira Biosciences (NASDAQ:PCRX) Q1 2026 Results Beat Estimates as Key Pipeline Catalysts Near - ChartMill

Apr 30, 2026
pulisher
Apr 30, 2026

Q1 2026 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q1 Adjusted EPS $0.60 per Share, vs. FactSet Est of $0.55 - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Earnings Flash (PCRX) Pacira BioSciences, Inc. Reports Q1 Revenue $177.4M, vs. FactSet Est of $171.8M - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences (NASDAQ: PCRX) Q1 2026 revenue reaches $177M - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences (NASDAQ: PCRX) grows Q1 revenue 5% and reaffirms 2026 guidance - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Pacira BioSciences 1Q EPS 7c >PCRX - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

MSN - MSN

Apr 30, 2026
pulisher
Apr 30, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 30, 2026
pulisher
Apr 29, 2026

Pacira BioSciences Inc. (PCRX) Stock Rises on Q4 2025 Earnings - Quiver Quantitative

Apr 29, 2026
pulisher
Apr 28, 2026

Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders - The Manila Times

Apr 28, 2026
pulisher
Apr 28, 2026

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - 富途牛牛

Apr 28, 2026
pulisher
Apr 27, 2026

Is It Too Late to Buy Pacira BioSciences Inc (PCRX) After 4.3% R - GuruFocus

Apr 27, 2026

Pacira Biosciences Inc (PCRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
RDY RDY
$13.26
price down icon 0.67%
$22.99
price up icon 2.13%
RGC RGC
$27.27
price down icon 0.33%
$135.06
price up icon 0.74%
$15.52
price up icon 2.11%
$572.20
price down icon 1.55%
大文字化:     |  ボリューム (24 時間):